As I recall,the Phase 11B trials were better than 90% successful. Not only was there no trace of any virus, but the white cell count improved also.
Time and money is our enemy. As time passes there will be additional competitors soaking up the market. Successful treatment using existing products will reduce the market pool.
Countries where the HIV virus may be increasing are too poor to be able to pay for the cost of treatment.
The Phase 111 trials are so expensive that Avexa will need to dilute it's interest to even as low as 25% to continue in the game.
AVX Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
